Anti-tumour necrosis factor therapy for ankylosing spondylitis - Unresolved issues

Rheumatology

Volumn 46, Issue 6, 2007, Pages 899-901

  Jois, R N ^a   Gaffney, K ^a   Keat, A ^b  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EARLY DIAGNOSIS; EDITORIAL; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; WELLBEING;

ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; HEALTH SERVICES ACCESSIBILITY; HUMANS; PATIENT SELECTION; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447303500     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem012     Document Type: Editorial

References (36)

1. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
2. Davis JC Jr, van der Heijde D. Braun J et al. Enbrel ankylosing spondylitis study group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized controlled trial. Arthritis Rheum 2003;48:3230-6.
3. van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
4. Braun J, Landewe R, Hermann KA et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
5. Baraliakos X, Brandt J, Listing J et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63.
6. Haibel H, Rudwaleit M, Brandt HC et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678-81.
7. Welsing P, Landewe R, van Riel P M et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis. A longitudinal analys. Arthritis Rheum 2004;50:2082-93.
8. Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
9. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumor necrosis factor a treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004;63:1670-72.
10. van der Heijde D, Han C, De Vlam K et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Rheum 2006;55:569-74.
11. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor a antibody infliximab. Ann Rheum Dis 2005;64:1462-66.
12. van der Horst-Bruinsma I, Wanders A, van der Heijde D, Fatenejad S. Radiographic results from a long-term multicenter trial of etanercept in patients with ankylosing spondylitis. Rheumatology 2006;45:15.
13. Barkham N, Kong KO, Tennant A et al. The unmet need for anti-tumor necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology 2005;44:1277-81.
14. Keat A, Barkham N, Bhalla A et al. BSR guidelines for prescribing TNIF-α blockers in adults with ankylosing spondylitis. Report of a working party of the British society for rheumatology. Rheumatology 2005;44:939-47.
15. Kay LJ, Griffiths ID. UK consultant rheumatologists' access to biologic agents and views on the BSR Biologies Register. Rheumatology 2006;45:1376-79.
16. Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
17. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal; results from a twelve-month randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
18. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumor necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
19. Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A. Etanercept may benefit early-onset ankylosing spondylitis. J Rheum 2006;33:1634-36.
20. Feldtkeller E, Khan MA, van der Heijde, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B 27 negative vs positive patients with ankylosing spondylitis. Rheumatol Int 2003,23:61-6.
21. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
22. van der Linden S, van Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
23. Yu W, Feng F, Dion E, Yang H, Jiang M, Genant HK. Comparison of radiography, computed tomography and magnetic resonance imaging in the detection of sacroilitis accompanying ankylosing spondylitis. Skeletal Radiol 1998;27:311-20.
24. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis: A reassessment of clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569-78.
25. Boyer GS, Templin DW, Bowler A et al. A comparison of patients with spondyloarthropathy seen in speciality clinics with those identified in a community-wide espidemiologic study. Has the classic case misled us? Arch Intern Med 1997;157:2111-17.
26. Sieper J, Dijkmans BAC, van der Linden S et al. Sustained efficacy and safety of patients with ankylosing spondylitis treated with etanercept: Outcomes at 148-160 weeks of long term therapy. Arthritis Rheum 2006;54:S473.
27. Baraliakos X, Listing J, Brandt J et al. Persistent clinical efficacy and safety over 5 years of treatment with anti-TNF a agent infliximab in patients with ankylosing spondylitis. Arthritis; Rheum 2006;54:S720.
28. Baraliakos X, Listing J, Brandt J, Rudwaliet M, Sieper J, Braun J et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:R439-44.
29. Jois RN, Leeder J, Gibb A et al. Low-dose infliximab treatment for ankylosing spondylitis - clinically- and cost-effective. Rheumatology 2006;45:1566-69.
30. Keeling S, Oswald A, Russell AS, Maksymowych WP. Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol 2006;33:558-61.
31. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53(Suppl V):v1-16.
32. Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006;33:289-95.
33. Boonen A, Chorus A, Miedema H et al. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis 2001;60:1033-39.
34. Barlow JH, Wright CC, Williams B, Keat A. Work disability among people with ankylosing spondylitis. Arthritis Rheum 2001;45:424-29.
35. Braun J, Brandt J, Listing J et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
36. Seiper J, Baraliakos X, Listing J et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with anli-tumor necrosis factor agent infliximab. Rheumatology 2005;44:1525-30.